Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

In vitro phase I metabolism of the synthetic cannabimimetic JWH-018.

Wintermeyer A, Möller I, Thevis M, Jübner M, Beike J, Rothschild MA, Bender K.

Anal Bioanal Chem. 2010 Nov;398(5):2141-53. doi: 10.1007/s00216-010-4171-0. Epub 2010 Sep 14.

PMID:
20838779
2.

Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS.

Zhang Q, Ma P, Cole RB, Wang G.

Anal Bioanal Chem. 2006 Nov;386(5):1345-55. Epub 2006 Sep 6.

PMID:
16955257
3.

Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.

Möller I, Wintermeyer A, Bender K, Jübner M, Thomas A, Krug O, Schänzer W, Thevis M.

Drug Test Anal. 2011 Sep;3(9):609-20. doi: 10.1002/dta.158. Epub 2010 Sep 24.

PMID:
20872894
4.

Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures.

Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2519-26. doi: 10.1016/j.jchromb.2011.07.004. Epub 2011 Jul 18.

PMID:
21803006
5.
6.

Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids.

Gambaro V, Arnoldi S, Bellucci S, Casagni E, Dell'Acqua L, Fumagalli L, Pallavicini M, Roda G, Rusconi C, Valoti E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 15;957:68-76. doi: 10.1016/j.jchromb.2014.03.001. Epub 2014 Mar 12.

PMID:
24657413
7.
8.

Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures.

Grigoryev A, Savchuk S, Melnik A, Moskaleva N, Dzhurko J, Ershov M, Nosyrev A, Vedenin A, Izotov B, Zabirova I, Rozhanets V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 1;879(15-16):1126-36. doi: 10.1016/j.jchromb.2011.03.034. Epub 2011 Mar 26.

PMID:
21481654
9.

Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans.

Watanabe S, Kuzhiumparambil U, Winiarski Z, Fu S.

Forensic Sci Int. 2016 Apr;261:33-42. doi: 10.1016/j.forsciint.2015.12.023. Epub 2015 Dec 21.

PMID:
26907475
10.

Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites.

ElSohly MA, Gul W, Elsohly KM, Murphy TP, Madgula VL, Khan SI.

J Anal Toxicol. 2011 Sep;35(7):487-95.

PMID:
21871158
12.

Detection and tentative identification of urinary phase I metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC-MS and LC-MS/MS.

Kavanagh P, Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 1;934:102-8. doi: 10.1016/j.jchromb.2013.07.005. Epub 2013 Jul 15.

PMID:
23917406
13.

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL.

Toxicol Appl Pharmacol. 2013 Jun 1;269(2):100-8. doi: 10.1016/j.taap.2013.03.012. Epub 2013 Mar 26.

14.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL.

PLoS One. 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917. Epub 2011 Jul 6.

15.

Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.

Hutter M, Moosmann B, Kneisel S, Auwärter V.

J Mass Spectrom. 2013 Jul;48(7):885-94. doi: 10.1002/jms.3229.

PMID:
23832945
17.

Prevalence of synthetic cannabinoids in U.S. athletes: initial findings.

Heltsley R, Shelby MK, Crouch DJ, Black DL, Robert TA, Marshall L, Bender CL, DePriest AZ, Colello MA.

J Anal Toxicol. 2012 Oct;36(8):588-93. doi: 10.1093/jat/bks066. Epub 2012 Aug 7.

PMID:
22872465
18.

Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing.

Beuck S, Möller I, Thomas A, Klose A, Schlörer N, Schänzer W, Thevis M.

Anal Bioanal Chem. 2011 Aug;401(2):493-505. doi: 10.1007/s00216-011-4931-5. Epub 2011 Apr 1.

PMID:
21455647
19.

First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry.

Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA.

AAPS J. 2013 Oct;15(4):1091-8. doi: 10.1208/s12248-013-9516-0. Epub 2013 Aug 3.

20.

A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL.

Chem Res Toxicol. 2012 Apr 16;25(4):825-7. doi: 10.1021/tx3000472. Epub 2012 Mar 15.

Supplemental Content

Support Center